2. Search Result
Search Result
Results for "

18F

" in MedChemExpress (MCE) Product Catalog:

93

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

3

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W087028
    NOTA-NHS ester

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents CXCR Cancer
    NOTA-NHS ester is a chelating agent. NOTA-NHS ester can be coupled with T140 (HY-P4810) to produce NOTA-T140. NOTA-T140 can be radiolabeled with Al[ 18F]. The uptake of Al[ 18F]NOTA-T140 in tumors is correlated with the expression level of CXCR4. Al[ 18F]NOTA-T140 can be used in tumor PET imaging studies. NOTA-NHS ester can be used for fluorescent labeling .
    NOTA-NHS ester
  • HY-B1516
    Alovudine
    3 Publications Verification

    3'-Fluoro-3'-deoxythymidine; 3′-Deoxy-3′-fluorothymidine; FLT

    		 DNA/RNA Synthesis Orthopoxvirus Infection Cancer
    Alovudine (3'-Fluoro-3'-deoxythymidine) is a mtDNA synthesis inhibitor and a marker of DNA synthesis. Alovudine is less susceptible to inflammatory changes than 18F-Fluorodeoxyglucose (FDG) and thus is a better biomarker in pancreatic cancer. Alovudine shows anti-orthopoxvirus and anti-leukemic activity .
    Alovudine
  • HY-120947
    AV-105

    		Drug Intermediate Neurological Disease
    AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
    AV-105
  • HY-141637
    2-Deoxy-2-fluoro-D-glucose
    2 Publications Verification

    2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose

    		 Biochemical Assay Reagents Cancer
    2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with 18F for positron emission tomography (PET) imaging. 18F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .
    2-Deoxy-2-fluoro-D-glucose
  • HY-160116
    α-Synuclein aggregate binder 1

    		Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein Neurological Disease
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
    α-Synuclein aggregate binder 1
  • HY-P99364
    Icrucumab
    1 Publications Verification

    Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

    		 VEGFR Apoptosis p38 MAPK Akt Endocrinology Cancer
    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .
    Icrucumab
  • HY-19997
    Mannose triflate

    TATM

    		 Biochemical Assay Reagents Cancer
    Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .
    Mannose triflate
  • HY-117756
    Piflufolastat

    DCFPYL

    		 PSMA Cancer
    Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an 18F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer .
    Piflufolastat
  • HY-101185
    T808

    		Tau Protein Neurological Disease
    T808 is a selective tau protein-targeting ligand. T808 can be used to synthesize [ 18F]-T808, a highly selective tau protein positron emission tomography (PET) tracer. T808 can also be used to synthesize [ 3H]-T808, a marker for in vitro experiments. T808 can be used for the research of alzheimer’s disease .
    T808
  • HY-152148
    JZP-MA-11

    		MAGL Neurological Disease
    JZP-MA-11 is a brain-penetrant positron emission tomography (PET) ligand targeting the brain endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .
    JZP-MA-11
  • HY-135714
    Bavarostat

    EKZ-001

    		 HDAC Microtubule/Tubulin Neurological Disease Cancer
    Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent HDAC6 inhibitor and PET radiotracer, with an IC50 as low as 17 nM against human HDAC6. Bavarostat can be labeled with 18F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .
    Bavarostat
  • HY-100705
    DMNB

    6-Nitroveratraldehyde

    		 Drug Intermediate Neurological Disease
    DMNB (6-Nitroveratraldehyde) is a photolabile proton donor that releases acidic substances when excited at a wavelength of 405 nM. DMNB can be used for the synthesis of no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). DMNB is also applicable to the preparation of o-nitroaryl-bis (5-methylfur-2-yl) methanes and the synthesis of alpha-asarone (HY-N0700). DMNB is an enzyme involved in the non-homologous end joining (NHEJ) pathway responsible for DNA double-strand break (DSB) repair. DMNB can be used in PET studies of the dopaminergic system .
    DMNB
  • HY-129650
    Florbetapir
    1 Publications Verification

    AV-45; Flobetapir

    		 Biochemical Assay Reagents Others
    Flobetapir (AV-45) may be a well-tolerated imaging agent. Flobetapir synthesizes Florbetapir (18F) that is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18 .
    Florbetapir
  • HY-153550
    PSMA-1007

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    PSMA-1007
  • HY-400882
    Tosylate-DPA-714

    		Drug Derivative Drug Intermediate TSPO Neurological Disease Inflammation/Immunology
    Tosylate-DPA-714 is a GMP-grade precursor for the radiosynthesis of DPA-714 (HY-122607). It crosses the blood-brain barrier and exhibits steroidogenic activity. DPA-714 is a specific ligand for the 18 kDa translocator protein (TSPO) with a Ki of 7.0 nM. Tosylate-DPA-714 is safe and does not bind to central benzodiazepine receptors (benzodiazepine receptor). As a radiolabeling precursor, Tosylate-DPA-714 reacts with 18F via nucleophilic aliphatic substitution to form 18F-DPA-714, enabling specific targeted binding to TSPO. 18F-DPA-714 accurately reflects the level of neuroinflammation mediated by microglial activation, and is used for PET molecular imaging of neurological diseases such as Alzheimer's disease and multiple sclerosis .
    Tosylate-DPA-714
  • HY-141647
    [18F]-Labeled L-dopa precursor

    		Dopamine Receptor Drug Intermediate Others
    [18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa .
    [18F]-Labeled L-dopa precursor
  • HY-100275
    MK-3328

    		Amyloid-β Neurological Disease
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging .
    MK-3328
  • HY-139048
    Fluoroethylnormemantine

    		iGluR Neurological Disease
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine
  • HY-179492
    ACI-19278

    		hnRNP Neurological Disease
    ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [ 18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions .
    ACI-19278
  • HY-135497
    Fallypride

    		Dopamine Receptor Neurological Disease
    Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( 18F), can be used as a positron emission tomography (PET) radiotracer .
    Fallypride
  • HY-159045
    F-SAHA

    p-Fluoro-SAHA

    		 HDAC Cancer
    F-SAHA is a HDAC inhibitor (HDACi) and its 18F labeled derivative can be used in tumor imaging research .
    F-SAHA
  • HY-76573
    ML-10

    		Apoptosis Cardiovascular Disease Cancer
    ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with 18F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential .
    ML-10
  • HY-164576
    NCS-MP-NODA

    NODA-Bz-SCN

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    NCS-MP-NODA (NODA-Bz-SCN) is a bifunctional chelator that can be used to bind to the labeled peptide DK222 with high specificity for PD-L1. The corresponding fluorinated radioactive is synthesized by the aluminum fluoride method, and NCS-MP-NODA targets DK222 to obtain the radioactive analog [18/19F]DK222. [18F]DK222 can quantify PD-L1 in vivo via PET tracking in xenograft models of multiple cancer types.
    NCS-MP-NODA
  • HY-19888
    GSK-1482160

    		P2X Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI) .
    GSK-1482160
  • HY-100723
    THK-523

    		Amyloid-β Neurological Disease
    THK-523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo. 18F-THK523 is a potent tau imaging radiotracer. 18F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease .
    THK-523
  • HY-175229
    PSMA ligand 1

    		PSMA Cancer
    PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. The [ 18F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer .
    PSMA ligand 1
  • HY-102089
    Fluoroclebopride

    		Dopamine Receptor Neurological Disease
    Fluoroclebopride binds reversibly to dopamine receptors. 18F labeled fluoroclebopride has been used as a probe for studying D2/D3 receptor availability via PET in various monkey models .
    Fluoroclebopride
  • HY-172205
    CHL2310

    		Cytochrome P450 Cancer
    CHL2310 is the inhibitor for CYP46A1 with an IC50 of 0.11 nM, and a Kd of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive 18F .
    CHL2310
  • HY-135859
    NH2-MPAA-NODA

    		ADC Linker Cancer
    NH2-MPAA-NODA is a nitroveratryl-based photocleavable linker, it has a NODA motif and a methyl phenyl acetic acid (MPAA) backbone . NH2-MPAA-NODA can be used as a radiolabel by labeling with 18F-fluoride.
    NH2-MPAA-NODA
  • HY-135859A
    NH2-MPAA-NODA TFA

    		ADC Linker Cancer
    NH2-MPAA-NODA TFA is a nitroveratryl-based photocleavable linker, it has a NODA motif and a methyl phenyl acetic acid (MPAA) backbone . NH2-MPAA-NODA can be used as a radiolabel by labeling with 18F-fluoride.
    NH2-MPAA-NODA TFA
  • HY-175685
    FAP-IN-7

    		FAP Cancer
    FAP-IN-7 (Compound 5b) is a FAP18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .
    FAP-IN-7
  • HY-146694
    RIPK2-IN-1

    		RIP kinase Anaplastic lymphoma kinase (ALK) Inflammation/Immunology
    RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC50 of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC50 of 5 nM. RIPK2-IN-1 has an IC50 of 390 nM on RIPK2/NOD2 in cell assay .
    RIPK2-IN-1
  • HY-163281
    FSY-OSO2F

    		Fluorescent Dye Cancer
    FSY-OSO2F shows an uptake in MCF-7 cells through the regulation of L-Tyr, ASC, and ASC2 transporters. FSY-OSO2F can be used as a PET tracer, when labeled with 18F, and exhibits good uptake and good contrast in MCF-7 and 22Rv1 subcutaneous tumors .
    FSY-OSO2F
  • HY-P10978
    NK224

    		PD-1/PD-L1 Cancer
    NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( 68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .
    NK224
  • HY-174977
    P2Y12R ligand-1

    		P2Y Receptor Neurological Disease
    P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y12R ligand with a Ki value of 17.1 nM. P2Y12R ligand-1 labeled with [ 18F] can be used in studies of brain PET imaging .
    P2Y12R ligand-1
  • HY-154850
    F-CRI1

    		STING Cancer
    F-CRI1 is a potent STING agonist with a Kd value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment .
    F-CRI1
  • HY-158326
    FAP-IN-4

    		FAP Cancer
    FAP-IN-4 (Comp 10) is a fibroblast activation protein (FAP) inhibitor and a 18F-labeled PET tracer targeting FAP. FAP-IN-4 can be used for cancer research .
    FAP-IN-4
  • HY-P5053
    Galacto-RGD

    		Radionuclide-Drug Conjugates (RDCs) Integrin Cancer
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Galacto-RGD
  • HY-P5025
    Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle)

    Azido-c(RGDyK)

    		 Drug Intermediate Others
    Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [ 18F]FPyKYNE-c(RGDyK) .
    Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle)
  • HY-149869
    PSMA-IN-3

    		PSMA Cancer
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
    PSMA-IN-3
  • HY-154802
    TCO-GK-PEG4-NHS ester

    		ADC Linker Radionuclide-Drug Conjugates (RDCs) Cancer
    TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to HER2 . TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
    TCO-GK-PEG4-NHS ester
  • HY-174978
    SK60

    		Isocitrate Dehydrogenase (IDH) Others
    SK60 is a dimethylated derivative of GSK321 (HY-18948) with low nanomolar potency and high selectivity for IDH1R132H (IC50 = 14.5 nM). SK60 can be used as a tracer for brain imaging with the fluorescent label [ 18F] .
    SK60
  • HY-175330
    FAP-IN-6

    		FAP Cancer
    FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC50 of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research .
    FAP-IN-6
  • HY-157556
    BPP-2

    		GHSR Others
    BPP-2 is a GHSR ligand with an F element. Using 18F isotope labeling BPP-2, a PET probe targeting GHSR can be obtained. The binding affinity Ki of 18F-BPP-2 for GHSR is 274 nM .
    BPP-2
  • HY-101182
    THK-5117

    		Microtubule/Tubulin Neurological Disease
    THK-5117, an arylquinoline derivative, displays high binding affinity to tau fibrils with a Ki of 10.5 nM. THK-5117 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD)  brain homogenates. 18F-THK-5117 has the potential to act as a tau imaging PET probe .
    THK-5117
  • HY-164475
    PARP1-IN-29

    		PARP Cancer
    PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .
    PARP1-IN-29
  • HY-175014
    LGT-1

    		PD-1/PD-L1 Biochemical Assay Reagents Cancer
    LGT-1 is a PD-L1 ligand. LGT-1 labeled with 18F has an excellent specific uptake in B16-F10 tumor cells, and shows a high tumor uptake but a low liver uptake with good stability in B16-F10 tumor-bearing mice model. LGT-1 can be used as a radiotracer for PET imaging of PD-L1 expression in tumors .
    LGT-1
  • HY-D2343
    PB0822

    		Biochemical Assay Reagents Neurological Disease
    PB0822 can be used for in vivo PET imaging when labeled with [ 18F]fluoride. [ 18F]PB0822 is a PET radioligand. [ 18F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ 18F]PB0822 can be used for Alzheimer’s Disease research .
    PB0822
  • HY-121659
    DCFBC

    		PSMA Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
    DCFBC
  • HY-113719
    VM4-037

    		Carbonic Anhydrase Cancer
    VM4-037 can be used for the synthesis of VM4-037(18F). VM4-037(18F) is a fluorinated PET imaging agent for carbonic anhydrase IX .
    VM4-037

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: